Semaglutides such as Ozempic and Wegovy have been in the news so much lately that they’ve become virtually “household names” when it comes to weight loss. These drugs, originally intended to help control Type II diabetes, are commonly being used “off-label” because they’re very effective at helping people gain metabolic control.
However, the rising popularity of these drugs has also brought to light some serious health concerns. That includes the potential to induce gastroparesis.
How are the two related?
Semaglutides mimic the GLP-1 hormone that the human body creates to regulate blood sugar by increasing insulin secretion and slowing down how fast someone’s stomach empties after eating. This delayed gastric emptying makes it easier for someone using the drug to feel sated, which ultimately helps with weight loss. The drug class has been hailed as a miracle treatment for obesity.
However, the very same mechanism that makes semaglutides highly effective for treating obesity can also negatively affect the gastrointestinal system and cause gastroparesis. Gastroparesis is sometimes called “stomach paralysis.” With this condition, the stomach takes too long to empty its contents into the small intestine.
Symptoms include:
- Nausea and vomiting
- Bloating
- Abdominal pain
- Heartburn or acid reflux
While gastroparesis can start for various reasons – and even occur as a symptom of diabetes itself – evidence increasingly suggests that semaglutides increase the chances someone will develop the condition or have their condition worsen.
The potential link between semaglutides and gastroparesis is concerning because of the risk of misdiagnosis (when a physician mistakes gastroparesis for another condition), which can lead to worsening problems and permanent damage. It can also lead to malnutrition and unhealthy weight loss, affecting a patient’s quality of life.
If you or your loved one developed gastroparesis after the use of semaglutides, it may be wise to seek a legal take on whether or not you have a valid legal claim against the drug manufacturer and/or other parties.